| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
(Z)-PUGNAc targets O-GlcNAcase (OGA), the enzyme that catalyzes the removal of O-GlcNAc post-translational modifications from serine and threonine residues of proteins. By inhibiting OGA, (Z)-PUGNAc prevents the deglycosylation of O-GlcNAcylated proteins, leading to increased levels of O-GlcNAc modification on cellular proteins. It also inhibits β-hexosaminidase. This modulation of O-GlcNAc signaling affects numerous cellular processes including transcription, signaling, and metabolism.
|
|---|---|
| ln Vitro |
In HeLa and HEK cell cultures, (Z)-PugNAc increases the yearly import of O-GlcNAc onto proteins [1].
In vitro, (Z)-PUGNAc amplifies the incorporation of O-GlcNAc on proteins within both HeLa and HEK cell systems. It is a more potent inhibitor of NCOAT than the (E) isomer in both in vitro biochemical assays and in cell-based systems. The compound is used to study the functional consequences of increased O-GlcNAcylation on protein function, cell signaling, and gene expression. It shows activity at nanomolar to low micromolar concentrations in various cell types. |
| ln Vivo |
In vivo, (Z)-PUGNAc has been used to elevate O-GlcNAc levels in animal models to study the physiological roles of O-GlcNAc modification. Inhibition of O-GlcNAcase leads to increased global O-GlcNAcylation in tissues, which has been associated with neuroprotective effects, modulation of insulin signaling, and regulation of circadian rhythms. Specific in vivo efficacy data for disease models are available in the literature, though detailed protocols vary depending on the experimental model and route of administration.
|
| Enzyme Assay |
For enzyme inhibition assays, recombinant O-GlcNAcase or NCOAT is incubated with a fluorogenic substrate such as 4-methylumbelliferyl-N-acetyl-β-D-glucosaminide (4-MU-GlcNAc) in assay buffer (50 mM sodium citrate, pH 6.0, 0.1% BSA) at 37°C. The test compound is added at various concentrations (typically 0.1-1000 nM). Fluorescence is measured at excitation 360 nm and emission 460 nm over time to determine initial reaction rates. IC50 values are calculated by fitting dose-response curves.
|
| Cell Assay |
For cell-based O-GlcNAc elevation studies, HeLa or HEK293 cells are cultured in complete medium and treated with (Z)-PUGNAc at concentrations ranging from 1-100 µM for 4-24 hours. Cells are harvested and lysed, and protein lysates are subjected to Western blot analysis using anti-O-GlcNAc antibodies (such as RL2 or CTD110.6) to detect increased O-GlcNAcylation. Nuclear and cytoplasmic fractions can be prepared to assess compartment-specific effects on O-GlcNAc modification.
|
| Animal Protocol |
For in vivo studies, (Z)-PUGNAc is typically administered via intraperitoneal injection in mice at doses ranging from 1-50 mg/kg, depending on the experimental model. Tissues are collected at various time points post-injection and homogenized for Western blot analysis of O-GlcNAc levels. In disease models such as diabetes or neurodegeneration, animals are treated chronically with (Z)-PUGNAc and monitored for phenotypic changes. Glucose tolerance tests and behavioral assays may be performed to assess functional outcomes of O-GlcNAc elevation.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of (Z)-PUGNAc have been partially characterized. It is cell-permeable and shows good tissue penetration. The compound is soluble in DMSO (up to 35 mg/mL) and DMF (10 mg/mL), with limited solubility in PBS (1 mg/mL). Storage is recommended at -20°C. The compound is stable as a crystalline solid. Further detailed PK parameters such as half-life, bioavailability, and clearance would require specific studies.
|
| Toxicity/Toxicokinetics |
In cell-based assays, (Z)-PUGNAc is generally well-tolerated at concentrations up to 100 µM for short-term treatments. No specific toxicological data have been reported in the available literature. As a tool compound for studying O-GlcNAc biology, it is not intended for therapeutic use. The compound should be handled with standard laboratory safety precautions. It is a research-use-only product and is not for human or veterinary use.
|
| References | |
| Additional Infomation |
(Z)-PUGNAc is a potent and cell-permeable inhibitor of O-GlcNAcase (OGA) that is vastly more active than the (E) isomer. It is used as a research tool to study O-GlcNAc post-translational modifications and their roles in cellular signaling, metabolism, and disease. The compound amplifies O-GlcNAc incorporation on proteins in HeLa and HEK cell systems. (Z)-PUGNAc is not approved for clinical use and is available for research purposes only.
|
| Molecular Formula |
C15H19N3O7
|
|---|---|
| Molecular Weight |
353.32726
|
| Exact Mass |
353.122
|
| CAS # |
132489-69-1
|
| PubChem CID |
9576811
|
| Appearance |
White to light yellow solid powder
|
| Density |
1.53g/cm3
|
| Melting Point |
172-175°C
|
| Index of Refraction |
1.638
|
| LogP |
-0.3
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
25
|
| Complexity |
507
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
CC(=O)N[C@@H]\1[C@H]([C@@H]([C@H](O/C1=N\OC(=O)NC2=CC=CC=C2)CO)O)O
|
| InChi Key |
PBLNJFVQMUMOJY-JXZOILRNSA-N
|
| InChi Code |
InChI=1S/C15H19N3O7/c1-8(20)16-11-13(22)12(21)10(7-19)24-14(11)18-25-15(23)17-9-5-3-2-4-6-9/h2-6,10-13,19,21-22H,7H2,1H3,(H,16,20)(H,17,23)/b18-14-/t10-,11-,12-,13-/m1/s1
|
| Chemical Name |
[(Z)-[(3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-ylidene]amino] N-phenylcarbamate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~141.51 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (3.54 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (3.54 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.25 mg/mL (3.54 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8302 mL | 14.1511 mL | 28.3022 mL | |
| 5 mM | 0.5660 mL | 2.8302 mL | 5.6604 mL | |
| 10 mM | 0.2830 mL | 1.4151 mL | 2.8302 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
